Jpmorgan Chase & CO Enlivex Therapeutics Ltd. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ENLV
# of Institutions
22Shares Held
2.1MCall Options Held
16.1KPut Options Held
3.4K-
Armistice Capital, LLC New York, NY1.7MShares$2.67 Million0.03% of portfolio
-
Morgan Stanley New York, NY245KShares$384,4800.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny71.7KShares$112,5510.0% of portfolio
-
Xtx Topco LTD London, X024.8KShares$38,9670.0% of portfolio
-
Act Capital Management, LLC Wayne, PA15KShares$23,5500.09% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $28.9M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...